Swiss biotech company Lumavita has tacked on an additional CHF6m ($5.53 million) to a Series A round initiated in September 2008. New investor HealthCap and existing investor Endeavour Vision provided the funds. The new funding brings Lumivita's total round to $22.2 million.
Lumavita is getting ready to launch its first product, FemiFect (pentamycin), for the treatment of all three causes of vaginitis. In March, the company gained preliminary marketing approval for the drug in Switzerland. The Series A extension will be used to build Lumavita's commercial partnering network as the company gets ready to launch FemiFect in 100 countries, and to finance two other pipeline projects.
"Our priorities are to gain FemiFect marketing approvals and launch the product in our target markets, alongside completing the development of both the high-dose formulation of FemiFect and of LMV-601, an anti-viral currently under evaluation for the treatment of cervical HPV," said Nicholas Benedict, CEO of Lumavita.
- here's Lumavita's release